Treating Mitral Regurgitation - Repair and Replace

Friday, May 13^th, 2022

12:30 PM - 1:15 PM EST

Boston Sheraton Hotel Convention Center, Constitution AB

Faculty

Dr. Maurice Sarano
Dr. Kevin Accola

Dr. David Adams
Dr. Vinod Thourani

Add to calendar

Introducing the new MITRIS RESILIA mitral valve

Saturday, May 14^th, 2022

12:30 PM - 1:30 PM EST

Hynes Convention Center, Room 302

Faculty

Dr. Richard Shemin

Dr. Randolph Chitwood Jr

Dr. Gorav Ailawadi
Dr. Kevin Accola

Add to calendar

Complex Aortic Root Care

Monday, May 16^th, 2022

12:15 PM - 1:15 PM EST

Hynes Convention Center, Room 304-306

Faculty

Dr. Joseph Bavaria

Dr. Ismail El-Hamamsy

Dr. Kim de la Cruz

Dr. Eric Roselli

Add to calendar

Visit Edwards Lifesciences at Booth #1609

Don't miss these presentations at AATS 2022 Annual Meeting:

Important Safety Information: RESILIA Tissue Devices

Indications: INSPIRIS RESILIA Aortic Valve - For use in replacement of native or prosthetic aortic heart valves. KONECT RESILIA Aortic Valved Conduit - For use in replacement of native or prosthetic aortic heart valves and the associated repair or replacement of a damaged or diseased ascending aorta. MITRIS RESILIA Mitral Valve - For use in replacement of native or prosthetic mitral heart valves. Contraindications: There are no known contraindications with the use of these RESILIA tissue heart valve devices. Complications and Side Effects: INSPIRIS RESILIA Aortic Valve - Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstruc­tural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, any of which could lead to reoperation, explantation, permanent disability, and death. Additional adverse events potentially associated with the use of polyester vascular grafts in the KONECT RESILIA AVC include hemorrhage, thrombosis, graft infection, embolism, aneurysm, pseudoaneurysm, seroma, occlusion (anastomotic intimal hyperplasia), immunological reaction to collagen (shown to be a weak immunogen; infrequent, mild, localized and self-limiting), intimal peel formation, and conduit dilatation. MITRIS RESILIA Mitral Valve - Thromboembolism, valve thrombosis, hemor­rhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, ventricular perforation by stent posts, any of which could lead to reoperation, explantation, permanent disability, and death. Warnings: INSPIRIS RESILIA Aortic Valve - DO NOT ADJUST THE VALVE DIAMETER BY EXPANDING THE BAND PRIOR TO OR DURING IMPLANTATION OF THE SURGICAL VALVE. The expandable band is not designed to allow for compression or expansion during implantation of the surgical valve. This will cause damage to the valve and may result in aortic incompetence. DO NOT PER­FORM STAND-ALONE BALLOON AORTIC VALVULOPLASTY PROCEDURES ON THIS VALVE FOR THE SIZES 19 – 25 mm as this may expand the valve causing aortic incompetence, coronary embolism or annular rupture. Valve-in-valve sizing in the INSPIRIS valve has only been tested with specific Edwards transcatheter heart valves. Use of other transcatheter valves may result in embolization of transcatheter devices anchored within or result in annular rupture.

 

CAUTION: Federal (USA) law restricts these devices to sale by or on the order of a physician. See Instructions for Use for full prescribing information.

 

Edwards, Edwards Lifesciences, the stylized E logo, HARPOON, INSPIRIS, INSPIRIS RESILIA, KONECT, KONECT RESILIA, MITRIS, MITRIS RESILIA, and RESILIA are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--US-7081 v1.0 | Manage Preferences | Privacy Policy

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com